BIVIBioVie Inc.
This year, BioVie Inc. has to prove it’s not just another biotech vaporware story — it has to deliver on its NE310 program, which is the only thing holding its stock above the $1.75 bear line. The next catalyst, on September 30, is a potential equity financing round that could push the stock toward $2.15 if it goes well, or drop to $1.75 if it fails. That’s the first step in a sequence of tests that could take the stock all the way to $4.70 by mid-2027, assuming every milestone is met and the market buys the story. If it stumbles at any point, the bear path will kick in, and the stock could fall back to $3.27 or worse. The question is: will the market believe in BioVie’s pipeline, or will it write the story off as another biotech disappointment?
The schedule
- Thu12Nov
Quarterly earnings report with guidance for Q4 2026 and 2027.
- Thu10Dec
Start of Phase 3 trial for NE310 in neurodegenerative disease.
- Sun13Dec
Presentation of updated Phase 2 clinical data for NE3107 in Parkinson's disease.
- Thu31Dec
Update on pipeline progress and strategic initiatives for 2027.
- Wed20Jan
Feedback from FDA on NE3107 Parkinson's disease Phase 2 data.
- Thu11Feb
- Thu13May
- Thu12Aug
Past
- Wed30Sep
Potential equity financing to fund clinical trials or expansion.
- Thu13Aug
Actual outcome: Bull · $2.19 at outcome
BioVie reported positive Phase 2 trial results for bezisterim in early Parkinson's disease, showing statistically significant improvements over placebo. The stock rallied due to the strong trial data and positive clinical outcomes, despite the EPS beat being neutral.
BioVie reports Q2 2026 earnings, with extreme focus on cash runway and burn rate.
